KRAS mutations in NSCLC are frequently seen in conjunction with mutations in tumor protein 53 (TP53) and serine-threonine kinase 11/liver kinase B1 (STK11/LKB1). This evidence concerns the gene TP53 and non-small cell lung carcinoma.